Beran, AzizullahMhanna, AsmaaMhanna, MohammedHassouneh, RamziAbuhelwa, ZiadMohamed, Mouhand F. H.Sayeh, WasefMusallam, RamiAssaly, RaghebAbdeljawad, Khaled2023-11-022023-11-022023-01-17Beran A, Mhanna A, Mhanna M, et al. Real-world effectiveness of COVID-19 vaccination in liver cirrhosis: a systematic review with meta-analysis of 51,834 patients. Proc (Bayl Univ Med Cent). 2023;36(2):151-156. Published 2023 Jan 17. doi:10.1080/08998280.2023.2165344https://hdl.handle.net/1805/36893SARS-CoV-2 vaccinations were found to be highly effective in phase 3 clinical trials. However, these trials have not reported data regarding the subgroup of liver disease or excluded patients with liver disease. The effectiveness of COVID-19 vaccines among liver cirrhosis (LC) patients is unclear. We conducted this meta-analysis to assess the effectiveness of SARS-CoV-2 vaccination in LC patients. A comprehensive literature search was conducted to include all the relevant studies that compared the outcomes of LC patients who received SARS-CoV-2 vaccines vs. unvaccinated patients. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated by the Mantel-Haenszel method within a random-effect model. Four studies with 51,834 LC patients (20,689 patients received at least one dose vs 31,145 were unvaccinated) were included. COVID-19–related complications, including hospitalization (RR 0.73, 95% CI 0.59–0.91, P = 0.004), mortality (RR 0.29, 95% CI 0.16–0.55, P = 0.0001), and need for invasive mechanical ventilation (RR 0.29, 95% CI 0.11–0.77, P = 0.01), were significantly lower in the vaccinated group compared to the unvaccinated group. SARS-CoV-2 vaccination in LC patients reduced COVID-19–related mortality, intubation, and hospitalization. SARS-CoV-2 vaccination is highly effective in LC. Further prospective studies, preferably randomized controlled trials, are necessary to validate our findings and determine which vaccine is superior in patients with LC.en-USPublisher PolicyChronic liver diseaseCOVID-19 vaccineLiver cirrhosisSARS-CoV-2 vaccineArticle